- Schuetz, Catharina;
- Hoenig, Manfred;
- Moshous, Despina;
- Weinstock, Christof;
- Castelle, Martin;
- Bendavid, Matthieu;
- Shimano, Kristin;
- Tolbert, Vanessa;
- Schulz, Ansgar S;
- Dvorak, Christopher C
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.